| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Ketoacidosis | 28 | 2025 | 169 | 8.640 |
Why?
|
| Diabetes Mellitus, Type 2 | 64 | 2025 | 1416 | 7.630 |
Why?
|
| Diabetes Mellitus, Type 1 | 37 | 2025 | 872 | 7.540 |
Why?
|
| Insulin-Secreting Cells | 21 | 2025 | 150 | 5.990 |
Why?
|
| Autoantibodies | 23 | 2024 | 467 | 4.120 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 9 | 2013 | 29 | 1.980 |
Why?
|
| Insulin | 15 | 2024 | 1260 | 1.680 |
Why?
|
| Blood Glucose | 19 | 2025 | 1196 | 1.530 |
Why?
|
| HIV Infections | 16 | 2024 | 2075 | 1.520 |
Why?
|
| Life Style | 16 | 2024 | 463 | 1.520 |
Why?
|
| Insulin Resistance | 13 | 2024 | 700 | 1.490 |
Why?
|
| HIV-1 | 7 | 2018 | 488 | 1.400 |
Why?
|
| Islets of Langerhans | 12 | 2024 | 178 | 1.390 |
Why?
|
| C-Peptide | 9 | 2024 | 116 | 1.300 |
Why?
|
| Obesity | 21 | 2024 | 2446 | 1.240 |
Why?
|
| Diabetes Mellitus | 8 | 2020 | 937 | 1.210 |
Why?
|
| Hypoglycemic Agents | 10 | 2025 | 490 | 1.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2013 | 272 | 1.020 |
Why?
|
| Weight Loss | 8 | 2021 | 516 | 1.010 |
Why?
|
| Humans | 129 | 2025 | 134084 | 0.980 |
Why?
|
| Metabolic Syndrome | 6 | 2022 | 365 | 0.970 |
Why?
|
| Hyperglycemia | 3 | 2025 | 242 | 0.970 |
Why?
|
| Disease Management | 3 | 2020 | 566 | 0.960 |
Why?
|
| Middle Aged | 57 | 2025 | 29394 | 0.930 |
Why?
|
| Biomarkers | 11 | 2025 | 3434 | 0.930 |
Why?
|
| Cardiovascular Diseases | 9 | 2024 | 2090 | 0.910 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 3 | 2021 | 13 | 0.900 |
Why?
|
| Gene Products, vpr | 3 | 2017 | 20 | 0.830 |
Why?
|
| Fabaceae | 1 | 2023 | 27 | 0.810 |
Why?
|
| Male | 78 | 2025 | 66093 | 0.790 |
Why?
|
| Energy Metabolism | 5 | 2021 | 814 | 0.790 |
Why?
|
| Triglycerides | 8 | 2015 | 617 | 0.790 |
Why?
|
| Hypolipidemic Agents | 7 | 2013 | 190 | 0.790 |
Why?
|
| Amino Acids | 1 | 2025 | 687 | 0.780 |
Why?
|
| Adult | 46 | 2025 | 31930 | 0.760 |
Why?
|
| Fenofibrate | 4 | 2013 | 61 | 0.760 |
Why?
|
| Female | 74 | 2025 | 71893 | 0.740 |
Why?
|
| Niacin | 4 | 2013 | 59 | 0.730 |
Why?
|
| Hypertriglyceridemia | 4 | 2013 | 114 | 0.730 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 318 | 0.730 |
Why?
|
| Overweight | 11 | 2024 | 387 | 0.720 |
Why?
|
| Thermogenesis | 1 | 2021 | 52 | 0.710 |
Why?
|
| Arginine | 3 | 2023 | 351 | 0.700 |
Why?
|
| Carnitine | 1 | 2021 | 78 | 0.700 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2021 | 82 | 0.690 |
Why?
|
| Adipose Tissue, White | 1 | 2021 | 93 | 0.690 |
Why?
|
| Adipose Tissue | 8 | 2024 | 510 | 0.680 |
Why?
|
| Lipid Metabolism | 7 | 2017 | 388 | 0.670 |
Why?
|
| Genetic Linkage | 1 | 2021 | 480 | 0.670 |
Why?
|
| Adiponectin | 4 | 2015 | 129 | 0.660 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 2 | 2018 | 11 | 0.630 |
Why?
|
| Ketosis | 1 | 2019 | 15 | 0.630 |
Why?
|
| Exercise | 5 | 2021 | 869 | 0.610 |
Why?
|
| Body Mass Index | 11 | 2024 | 1719 | 0.600 |
Why?
|
| Dyslipidemias | 3 | 2021 | 245 | 0.600 |
Why?
|
| Cholesterol, HDL | 4 | 2013 | 395 | 0.580 |
Why?
|
| Risk Reduction Behavior | 4 | 2016 | 150 | 0.580 |
Why?
|
| Insulysin | 1 | 2017 | 3 | 0.550 |
Why?
|
| Gene Products, env | 1 | 2017 | 17 | 0.550 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 9 | 0.550 |
Why?
|
| Diabetes Complications | 3 | 2020 | 206 | 0.540 |
Why?
|
| Machine Learning | 1 | 2020 | 339 | 0.530 |
Why?
|
| Glutamate Decarboxylase | 4 | 2014 | 42 | 0.520 |
Why?
|
| Glucose | 4 | 2022 | 927 | 0.510 |
Why?
|
| Culturally Competent Care | 1 | 2017 | 51 | 0.510 |
Why?
|
| Metabolomics | 4 | 2025 | 470 | 0.500 |
Why?
|
| Syndrome | 5 | 2021 | 1161 | 0.500 |
Why?
|
| Lipolysis | 5 | 2013 | 83 | 0.480 |
Why?
|
| Longitudinal Studies | 7 | 2019 | 1506 | 0.470 |
Why?
|
| Acanthosis Nigricans | 2 | 2022 | 11 | 0.460 |
Why?
|
| Virus Replication | 2 | 2018 | 637 | 0.440 |
Why?
|
| Health Behavior | 2 | 2017 | 405 | 0.440 |
Why?
|
| Monocytes | 2 | 2013 | 360 | 0.440 |
Why?
|
| Lipodystrophy | 2 | 2006 | 34 | 0.440 |
Why?
|
| Metabolic Diseases | 3 | 2014 | 139 | 0.430 |
Why?
|
| Malnutrition | 1 | 2017 | 221 | 0.430 |
Why?
|
| Aged | 30 | 2025 | 21772 | 0.420 |
Why?
|
| Anti-Retroviral Agents | 2 | 2013 | 150 | 0.410 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2013 | 128 | 0.410 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2013 | 42 | 0.400 |
Why?
|
| Diet Therapy | 1 | 2013 | 43 | 0.400 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2013 | 94 | 0.400 |
Why?
|
| Leptin | 2 | 2012 | 224 | 0.400 |
Why?
|
| Lipids | 4 | 2012 | 566 | 0.400 |
Why?
|
| Peptide Hormones | 2 | 2019 | 71 | 0.390 |
Why?
|
| Immune System | 1 | 2013 | 98 | 0.390 |
Why?
|
| Exercise Therapy | 2 | 2015 | 183 | 0.380 |
Why?
|
| Hyperlipidemias | 3 | 2013 | 198 | 0.370 |
Why?
|
| Pancreatitis | 1 | 2013 | 144 | 0.360 |
Why?
|
| Adipocytes | 5 | 2018 | 181 | 0.360 |
Why?
|
| Diabetic Angiopathies | 2 | 2015 | 72 | 0.360 |
Why?
|
| Adolescent | 17 | 2024 | 20610 | 0.360 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2014 | 90 | 0.350 |
Why?
|
| Heart Failure | 3 | 2022 | 2437 | 0.350 |
Why?
|
| DNA Methylation | 1 | 2017 | 1147 | 0.340 |
Why?
|
| Precision Medicine | 1 | 2014 | 357 | 0.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 506 | 0.340 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 131 | 0.330 |
Why?
|
| Body Weight | 3 | 2017 | 1041 | 0.330 |
Why?
|
| Dementia | 3 | 2023 | 488 | 0.330 |
Why?
|
| Sulfonylurea Compounds | 3 | 2025 | 19 | 0.330 |
Why?
|
| Body Composition | 6 | 2024 | 562 | 0.320 |
Why?
|
| Follow-Up Studies | 12 | 2022 | 5477 | 0.320 |
Why?
|
| Serum Response Factor | 3 | 2006 | 31 | 0.310 |
Why?
|
| Hormone Replacement Therapy | 1 | 2012 | 215 | 0.310 |
Why?
|
| Models, Biological | 2 | 2014 | 1539 | 0.310 |
Why?
|
| Cohort Studies | 6 | 2018 | 5217 | 0.310 |
Why?
|
| Thiazolidinediones | 2 | 2010 | 86 | 0.300 |
Why?
|
| Isoenzymes | 2 | 2006 | 231 | 0.300 |
Why?
|
| Human Growth Hormone | 2 | 2006 | 80 | 0.300 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 1812 | 0.300 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 14 | 0.290 |
Why?
|
| Physical Fitness | 4 | 2021 | 93 | 0.290 |
Why?
|
| Diagnosis, Differential | 3 | 2025 | 1978 | 0.290 |
Why?
|
| Metformin | 3 | 2025 | 165 | 0.280 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2013 | 139 | 0.280 |
Why?
|
| Prospective Studies | 7 | 2024 | 6601 | 0.270 |
Why?
|
| Autoimmunity | 4 | 2024 | 181 | 0.260 |
Why?
|
| Comparative Effectiveness Research | 2 | 2024 | 76 | 0.260 |
Why?
|
| Child | 14 | 2024 | 25870 | 0.260 |
Why?
|
| Case-Control Studies | 6 | 2025 | 3667 | 0.260 |
Why?
|
| Diet, Fat-Restricted | 1 | 2006 | 41 | 0.260 |
Why?
|
| PPAR alpha | 2 | 2017 | 55 | 0.240 |
Why?
|
| Phenotype | 7 | 2023 | 4570 | 0.240 |
Why?
|
| Mexican Americans | 1 | 2006 | 207 | 0.230 |
Why?
|
| Pyruvate Dehydrogenase Complex | 2 | 2016 | 12 | 0.230 |
Why?
|
| Critical Illness | 2 | 2009 | 629 | 0.230 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 426 | 0.230 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 1310 | 0.230 |
Why?
|
| Intensive Care Units | 1 | 2009 | 538 | 0.230 |
Why?
|
| Risk Factors | 12 | 2023 | 11180 | 0.230 |
Why?
|
| Kinetics | 3 | 2018 | 1357 | 0.230 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2025 | 97 | 0.220 |
Why?
|
| Intra-Abdominal Fat | 2 | 2016 | 59 | 0.220 |
Why?
|
| Pilot Projects | 3 | 2023 | 1492 | 0.220 |
Why?
|
| Community Health Workers | 1 | 2025 | 76 | 0.220 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2016 | 358 | 0.220 |
Why?
|
| Prognosis | 4 | 2024 | 5086 | 0.220 |
Why?
|
| HIV Integrase | 1 | 2024 | 4 | 0.220 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2024 | 12 | 0.220 |
Why?
|
| Double-Blind Method | 3 | 2013 | 1665 | 0.220 |
Why?
|
| Feedback | 1 | 2005 | 168 | 0.220 |
Why?
|
| Subcutaneous Fat | 1 | 2024 | 34 | 0.210 |
Why?
|
| Absorptiometry, Photon | 1 | 2024 | 206 | 0.210 |
Why?
|
| Racemethionine | 1 | 2023 | 6 | 0.210 |
Why?
|
| Adipokines | 1 | 2024 | 73 | 0.210 |
Why?
|
| Dietary Fats | 1 | 2005 | 300 | 0.210 |
Why?
|
| Cells, Cultured | 6 | 2025 | 3187 | 0.210 |
Why?
|
| Waist Circumference | 2 | 2017 | 95 | 0.200 |
Why?
|
| Immunoblotting | 2 | 2013 | 319 | 0.200 |
Why?
|
| Hospital Units | 1 | 2003 | 19 | 0.200 |
Why?
|
| Poverty | 2 | 2022 | 438 | 0.200 |
Why?
|
| Analysis of Variance | 3 | 2015 | 1044 | 0.200 |
Why?
|
| Uncompensated Care | 1 | 2003 | 12 | 0.200 |
Why?
|
| Methionine | 1 | 2023 | 105 | 0.200 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 703 | 0.200 |
Why?
|
| Bacteriuria | 1 | 2024 | 83 | 0.200 |
Why?
|
| Puberty | 2 | 2021 | 104 | 0.200 |
Why?
|
| Monitoring, Physiologic | 1 | 2005 | 388 | 0.190 |
Why?
|
| Genetic Loci | 3 | 2015 | 367 | 0.190 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2022 | 29 | 0.190 |
Why?
|
| Receptors, Ghrelin | 1 | 2022 | 29 | 0.190 |
Why?
|
| Citrulline | 1 | 2023 | 114 | 0.190 |
Why?
|
| Glutamine | 1 | 2023 | 222 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 3114 | 0.190 |
Why?
|
| Motor Activity | 1 | 2005 | 531 | 0.180 |
Why?
|
| Uncoupling Protein 1 | 1 | 2021 | 32 | 0.180 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2021 | 10 | 0.180 |
Why?
|
| Diabetic Neuropathies | 1 | 2021 | 65 | 0.170 |
Why?
|
| Adipose Tissue, Brown | 1 | 2021 | 87 | 0.170 |
Why?
|
| Body Temperature | 1 | 2021 | 130 | 0.170 |
Why?
|
| Oxidation-Reduction | 4 | 2006 | 470 | 0.170 |
Why?
|
| Prevalence | 4 | 2024 | 2684 | 0.170 |
Why?
|
| Adiposity | 3 | 2019 | 207 | 0.170 |
Why?
|
| Young Adult | 6 | 2018 | 9935 | 0.170 |
Why?
|
| Liver | 3 | 2019 | 1879 | 0.170 |
Why?
|
| Chromatography, Thin Layer | 2 | 2013 | 50 | 0.170 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 213 | 0.170 |
Why?
|
| Cysteine | 2 | 2011 | 143 | 0.170 |
Why?
|
| Sitagliptin Phosphate | 3 | 2025 | 8 | 0.160 |
Why?
|
| Liraglutide | 3 | 2025 | 15 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2024 | 13074 | 0.160 |
Why?
|
| Nitric Oxide | 2 | 2018 | 490 | 0.160 |
Why?
|
| Glycine | 2 | 2011 | 173 | 0.160 |
Why?
|
| DNA | 2 | 2017 | 1681 | 0.160 |
Why?
|
| CD36 Antigens | 1 | 2019 | 42 | 0.160 |
Why?
|
| Alleles | 4 | 2014 | 1716 | 0.160 |
Why?
|
| PPAR gamma | 2 | 2013 | 89 | 0.160 |
Why?
|
| Glutathione | 2 | 2011 | 201 | 0.160 |
Why?
|
| Cerebral Cortex | 1 | 2002 | 482 | 0.160 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 232 | 0.150 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 190 | 0.150 |
Why?
|
| Telemedicine | 1 | 2025 | 503 | 0.150 |
Why?
|
| Awareness | 1 | 2019 | 80 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 1492 | 0.150 |
Why?
|
| Metabolome | 1 | 2021 | 322 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2019 | 915 | 0.150 |
Why?
|
| Organ Size | 2 | 2014 | 467 | 0.150 |
Why?
|
| Immunoassay | 1 | 2018 | 139 | 0.140 |
Why?
|
| Pandemics | 2 | 2023 | 1190 | 0.140 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2018 | 36 | 0.140 |
Why?
|
| Glucose Clamp Technique | 1 | 2018 | 78 | 0.140 |
Why?
|
| Mutation, Missense | 3 | 2021 | 940 | 0.140 |
Why?
|
| Diet | 4 | 2013 | 1195 | 0.140 |
Why?
|
| Ornithine | 1 | 2018 | 33 | 0.140 |
Why?
|
| Liver X Receptors | 1 | 2017 | 19 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 867 | 0.140 |
Why?
|
| Protein Domains | 1 | 2018 | 260 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 797 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2020 | 3495 | 0.140 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 2539 | 0.140 |
Why?
|
| Cognition Disorders | 1 | 2021 | 579 | 0.130 |
Why?
|
| Physicians | 1 | 2024 | 639 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 3043 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 452 | 0.130 |
Why?
|
| Hippocampus | 1 | 2002 | 863 | 0.130 |
Why?
|
| Sexual Development | 1 | 2016 | 23 | 0.130 |
Why?
|
| Steroidogenic Factor 1 | 1 | 2016 | 37 | 0.130 |
Why?
|
| India | 1 | 2017 | 239 | 0.130 |
Why?
|
| Animals | 11 | 2025 | 36545 | 0.130 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 604 | 0.120 |
Why?
|
| Proteolysis | 1 | 2017 | 199 | 0.120 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2016 | 45 | 0.120 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2016 | 76 | 0.120 |
Why?
|
| Cardiology | 1 | 2021 | 521 | 0.120 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2016 | 100 | 0.120 |
Why?
|
| Genetic Variation | 4 | 2021 | 1626 | 0.120 |
Why?
|
| Fasting | 3 | 2007 | 308 | 0.120 |
Why?
|
| Lipoproteins, HDL | 2 | 2013 | 118 | 0.120 |
Why?
|
| Sex Factors | 2 | 2010 | 1387 | 0.120 |
Why?
|
| Carbon Isotopes | 2 | 2006 | 279 | 0.120 |
Why?
|
| Gene Frequency | 2 | 2010 | 779 | 0.120 |
Why?
|
| Claudins | 1 | 2015 | 31 | 0.120 |
Why?
|
| HeLa Cells | 1 | 2017 | 838 | 0.120 |
Why?
|
| Incidence | 1 | 2023 | 3416 | 0.120 |
Why?
|
| Esterification | 2 | 2006 | 13 | 0.110 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 346 | 0.110 |
Why?
|
| Ghrelin | 2 | 2022 | 55 | 0.110 |
Why?
|
| United States | 5 | 2021 | 11762 | 0.110 |
Why?
|
| Insulin Glargine | 2 | 2025 | 7 | 0.110 |
Why?
|
| Cell Differentiation | 5 | 2025 | 2044 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 546 | 0.110 |
Why?
|
| Mice | 7 | 2025 | 19047 | 0.110 |
Why?
|
| 3T3-L1 Cells | 1 | 2013 | 58 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2015 | 254 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 214 | 0.110 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2014 | 40 | 0.110 |
Why?
|
| Time Factors | 4 | 2015 | 6610 | 0.110 |
Why?
|
| PPAR-beta | 1 | 2013 | 4 | 0.110 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2014 | 71 | 0.110 |
Why?
|
| HIV | 1 | 2015 | 195 | 0.110 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 80 | 0.110 |
Why?
|
| PPAR delta | 1 | 2013 | 10 | 0.100 |
Why?
|
| Certification | 1 | 2014 | 73 | 0.100 |
Why?
|
| Hyperlipoproteinemia Type IV | 1 | 2013 | 3 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2022 | 2911 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2172 | 0.100 |
Why?
|
| Amylases | 1 | 2013 | 25 | 0.100 |
Why?
|
| Chemokine CCL5 | 1 | 2013 | 53 | 0.100 |
Why?
|
| Bicarbonates | 1 | 2013 | 100 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2015 | 2941 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2012 | 49 | 0.100 |
Why?
|
| Medical Records | 2 | 2004 | 194 | 0.100 |
Why?
|
| Lipase | 1 | 2013 | 98 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 239 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2014 | 337 | 0.100 |
Why?
|
| Actins | 2 | 2006 | 351 | 0.100 |
Why?
|
| Hepatocytes | 3 | 2017 | 245 | 0.100 |
Why?
|
| Sweetening Agents | 1 | 2012 | 37 | 0.100 |
Why?
|
| Cell Death | 1 | 2013 | 252 | 0.100 |
Why?
|
| Age of Onset | 2 | 2020 | 637 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2024 | 17538 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 429 | 0.090 |
Why?
|
| Fructose | 1 | 2012 | 63 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 627 | 0.090 |
Why?
|
| Endocrinology | 1 | 2014 | 135 | 0.090 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2011 | 15 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2015 | 1338 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2012 | 117 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 3754 | 0.090 |
Why?
|
| Protein Kinases | 1 | 2013 | 345 | 0.090 |
Why?
|
| Angiopoietins | 1 | 2011 | 21 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 756 | 0.090 |
Why?
|
| Educational Measurement | 1 | 2014 | 332 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 298 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 723 | 0.090 |
Why?
|
| Recurrence | 1 | 2015 | 1472 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2015 | 471 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2015 | 3742 | 0.090 |
Why?
|
| Palmitates | 2 | 2010 | 19 | 0.090 |
Why?
|
| Waist-Hip Ratio | 2 | 2010 | 60 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2011 | 489 | 0.090 |
Why?
|
| Texas | 3 | 2024 | 3716 | 0.090 |
Why?
|
| Alcoholism | 1 | 2013 | 253 | 0.080 |
Why?
|
| Genotype | 2 | 2013 | 2811 | 0.080 |
Why?
|
| Logistic Models | 1 | 2015 | 1909 | 0.080 |
Why?
|
| Inflammation | 2 | 2020 | 1594 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2015 | 1258 | 0.080 |
Why?
|
| Epitopes | 2 | 2014 | 446 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 822 | 0.080 |
Why?
|
| Homeostasis | 2 | 2012 | 751 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 1200 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2006 | 2301 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 1761 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2014 | 1039 | 0.080 |
Why?
|
| Energy Intake | 1 | 2012 | 518 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 560 | 0.080 |
Why?
|
| Homocysteine | 1 | 2009 | 120 | 0.070 |
Why?
|
| Amino Acid Substitution | 4 | 2015 | 414 | 0.070 |
Why?
|
| Cholesterol | 2 | 2009 | 575 | 0.070 |
Why?
|
| Macrophages | 1 | 2013 | 711 | 0.070 |
Why?
|
| Prediabetic State | 1 | 2009 | 63 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2013 | 1249 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 2175 | 0.070 |
Why?
|
| Glycerol | 2 | 2010 | 99 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3999 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2008 | 342 | 0.070 |
Why?
|
| Sulfur Radioisotopes | 1 | 2006 | 7 | 0.070 |
Why?
|
| Radioligand Assay | 1 | 2006 | 27 | 0.070 |
Why?
|
| Cognition | 2 | 2023 | 817 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2014 | 1062 | 0.070 |
Why?
|
| Radioimmunoassay | 1 | 2006 | 112 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2025 | 4934 | 0.060 |
Why?
|
| Apolipoprotein B-100 | 1 | 2006 | 39 | 0.060 |
Why?
|
| Calorimetry | 1 | 2006 | 63 | 0.060 |
Why?
|
| Macaca mulatta | 2 | 2019 | 513 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2006 | 206 | 0.060 |
Why?
|
| Genes, fos | 1 | 2006 | 15 | 0.060 |
Why?
|
| Deuterium | 1 | 2006 | 109 | 0.060 |
Why?
|
| Thinness | 1 | 2006 | 77 | 0.060 |
Why?
|
| Mitochondria | 2 | 2013 | 756 | 0.060 |
Why?
|
| Myoblasts, Skeletal | 1 | 2006 | 12 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2012 | 732 | 0.060 |
Why?
|
| Comorbidity | 2 | 2018 | 1625 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2018 | 247 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 323 | 0.060 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 145 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2011 | 877 | 0.060 |
Why?
|
| Nelson Syndrome | 1 | 2005 | 2 | 0.060 |
Why?
|
| Muscle Development | 1 | 2006 | 75 | 0.060 |
Why?
|
| Chylomicrons | 1 | 2005 | 9 | 0.060 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2005 | 81 | 0.060 |
Why?
|
| Algorithms | 1 | 2012 | 1735 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2006 | 650 | 0.060 |
Why?
|
| Pedigree | 2 | 2021 | 1713 | 0.060 |
Why?
|
| Cytokines | 2 | 2011 | 1400 | 0.060 |
Why?
|
| Clofibric Acid | 1 | 2004 | 3 | 0.060 |
Why?
|
| Postprandial Period | 1 | 2005 | 91 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 7216 | 0.060 |
Why?
|
| Shock, Septic | 1 | 2006 | 157 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2025 | 2562 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 333 | 0.060 |
Why?
|
| Hypotension | 1 | 2006 | 190 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2025 | 227 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 469 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 504 | 0.050 |
Why?
|
| DNA, Viral | 2 | 2016 | 500 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 289 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1306 | 0.050 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2004 | 77 | 0.050 |
Why?
|
| Exercise Test | 2 | 2015 | 264 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2004 | 130 | 0.050 |
Why?
|
| Histocompatibility Testing | 1 | 2003 | 151 | 0.050 |
Why?
|
| Viral Load | 1 | 2005 | 412 | 0.050 |
Why?
|
| Homeodomain Proteins | 2 | 2021 | 585 | 0.050 |
Why?
|
| Critical Care | 1 | 2009 | 693 | 0.050 |
Why?
|
| Health Promotion | 1 | 2006 | 405 | 0.050 |
Why?
|
| Integrases | 1 | 2024 | 163 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 41 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 444 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2003 | 70 | 0.050 |
Why?
|
| Leucine | 1 | 2003 | 312 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 165 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2022 | 30 | 0.050 |
Why?
|
| Trans-Activators | 2 | 2021 | 839 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2004 | 421 | 0.050 |
Why?
|
| Receptor, Insulin | 1 | 2022 | 70 | 0.050 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2021 | 41 | 0.050 |
Why?
|
| Gene Expression | 1 | 2006 | 1621 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 40 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 490 | 0.050 |
Why?
|
| Age Factors | 2 | 2011 | 2997 | 0.040 |
Why?
|
| Reference Values | 1 | 2002 | 740 | 0.040 |
Why?
|
| Weight Gain | 1 | 2024 | 413 | 0.040 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 2669 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2004 | 481 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 199 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 232 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 197 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2021 | 137 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 535 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2002 | 372 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 133 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 160 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2003 | 414 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 842 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 512 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 1421 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 735 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2003 | 429 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2002 | 1044 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 31 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 1488 | 0.040 |
Why?
|
| Cell Movement | 1 | 2002 | 920 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 1765 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2021 | 14867 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 1102 | 0.040 |
Why?
|
| Tenofovir | 1 | 2018 | 23 | 0.040 |
Why?
|
| Autoantigens | 1 | 2019 | 118 | 0.040 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 182 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2018 | 37 | 0.040 |
Why?
|
| Prodrugs | 1 | 2018 | 64 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2017 | 106 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 757 | 0.030 |
Why?
|
| Transfection | 2 | 2013 | 1096 | 0.030 |
Why?
|
| Sex Determination Processes | 1 | 2016 | 13 | 0.030 |
Why?
|
| Karyotype | 1 | 2016 | 33 | 0.030 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2016 | 27 | 0.030 |
Why?
|
| Gonads | 1 | 2016 | 35 | 0.030 |
Why?
|
| Dietary Proteins | 2 | 2012 | 252 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 410 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2016 | 204 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2015 | 1878 | 0.030 |
Why?
|
| Rats | 1 | 2002 | 3890 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2021 | 1421 | 0.030 |
Why?
|
| Infant | 2 | 2021 | 13230 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 649 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1095 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 370 | 0.030 |
Why?
|
| Metabolic Equivalent | 1 | 2014 | 6 | 0.030 |
Why?
|
| Hospitalization | 1 | 2003 | 1906 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2014 | 63 | 0.030 |
Why?
|
| Testis | 1 | 2016 | 433 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2014 | 78 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2014 | 83 | 0.030 |
Why?
|
| 3-Hydroxyacyl CoA Dehydrogenases | 1 | 2013 | 10 | 0.030 |
Why?
|
| Cell Count | 1 | 2014 | 241 | 0.030 |
Why?
|
| Receptors, Lipoprotein | 1 | 2013 | 11 | 0.030 |
Why?
|
| Fibric Acids | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cholesterol Esters | 1 | 2013 | 16 | 0.030 |
Why?
|
| Ovary | 1 | 2016 | 390 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 98 | 0.030 |
Why?
|
| Lipoproteins, VLDL | 1 | 2013 | 57 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 333 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 119 | 0.030 |
Why?
|
| Thiazoles | 1 | 2013 | 104 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 233 | 0.020 |
Why?
|
| Protein Stability | 1 | 2013 | 174 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 723 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 137 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 837 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 1627 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 317 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2014 | 338 | 0.020 |
Why?
|
| Haplotypes | 1 | 2014 | 560 | 0.020 |
Why?
|
| Neurons | 1 | 2002 | 2049 | 0.020 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 314 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 252 | 0.020 |
Why?
|
| Dairy Products | 1 | 2012 | 47 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2012 | 103 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 2578 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Isotopes | 1 | 2011 | 27 | 0.020 |
Why?
|
| F2-Isoprostanes | 1 | 2011 | 21 | 0.020 |
Why?
|
| Heterozygote | 1 | 2014 | 724 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 187 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2010 | 61 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 1433 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2011 | 238 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 221 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4878 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 565 | 0.020 |
Why?
|
| Glucokinase | 1 | 2009 | 16 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2009 | 20 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 451 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2009 | 31 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1140 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2009 | 77 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 370 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1858 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1156 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 905 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8617 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4807 | 0.020 |
Why?
|
| Nitrates | 1 | 2006 | 33 | 0.020 |
Why?
|
| Nitrogen Isotopes | 1 | 2006 | 63 | 0.020 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2006 | 9 | 0.020 |
Why?
|
| Nitrites | 1 | 2006 | 50 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 406 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2006 | 20 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2006 | 86 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 138 | 0.020 |
Why?
|
| Skin Pigmentation | 1 | 2005 | 29 | 0.020 |
Why?
|
| Glucagon | 1 | 2005 | 184 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2006 | 174 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3796 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 2137 | 0.010 |
Why?
|
| Serine | 1 | 2006 | 185 | 0.010 |
Why?
|
| Cicatrix | 1 | 2005 | 128 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 873 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2003 | 33 | 0.010 |
Why?
|
| Threonine | 1 | 2003 | 63 | 0.010 |
Why?
|
| Myotonin-Protein Kinase | 1 | 2003 | 45 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 139 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2006 | 549 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 284 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2003 | 151 | 0.010 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2003 | 121 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 382 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 2794 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3979 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1440 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 1712 | 0.010 |
Why?
|
| Myocardium | 1 | 2003 | 1046 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2860 | 0.010 |
Why?
|